Structural Genomics Consortium and collaborators release renewable recombinant antibodies for 12 high-impact epigenetics targets
Antibodies are first released in massive collaboration to create ‘master set’ of high-quality renewable epigenetics antibodies
TORONTO, June 4, 2012 /PRNewswire/ – The Structural Genomics Consortium (SGC),
a group of expert researchers in recombinant antibody technology from
the Universities of Toronto and Chicago and an industry partner have
entered into a pioneering public-private partnership to generate
renewable recombinant antibodies for epigenetic targets. The first set
of ten antibodies, released today, represent a major breakthrough in
quality and consistency, historically a significant issue in the
The SGC at the University of Toronto is spearheading the ambitious
project. The new antibodies will be featured on the independent
antibody review database 1DegreeBio.org.
“The partnership is on its way to producing a set of 200
highly-specific, highly-sensitive antibodies that are validated for
specific applications,” says Dr. Aled Edwards, Director and CEO, SGC.
“This is the first step toward developing a master set of quality
epigenetics antibodies that researchers can use for generations to
Inconsistency in antibody quality has plagued the scientific community
for decades. A lack of industry-wide standards and the high cost of
thoroughly validating each antibody generated an influx of products
that frequently do not perform as advertised, wasting hundreds of
millions of research dollars each year. The new renewable recombinant
antibodies are engineered to address these issues, and have been tested
for consistent performance across applications.
Validation data and community reviews of the new antibodies may be found
on 1DegreeBio.org. The release of these epigenetics-targeted antibodies
coincides with the launch of 1DegreeBio’s new Epigenetics Portal, where
epigenetics researchers can find targets, tools and product data
specific to their research.
“These reagents reflect a strong commitment to address a long-standing
quality issue in the community,” says Alex Hodgson, Managing Director,
1DegreeBio. “1DegreeBio is excited to support these and future
reagents, and be the venue to measure their impact.”
“Our group is committed to provide high quality antibody validation, ”
says Edwards. “We are delighted that 1DegreeBio will provide a vehicle
for the research community to share their experiences with these and
Epigenetic regulatory proteins are involved in a wide variety of chronic
diseases, such as cancer, and are the target of an explosive new field
of drug discovery.
About The Structural Genomics Consortium (SGC)
Located at the Universities of Toronto and Oxford, the not-for-profit
organization supports the discovery of new medicines by carrying out
open access research in structural and chemical biology. More than 200
researchers in academia and in six pharmaceutical companies collaborate
within SGC to accomplish these goals. The SGC is funded by the Canadian
Institutes for Health Research, Genome Canada, the Ontario’s Ministry
of Economic Development and Innovation, the Wellcome Trust, Abbott, Eli
Lilly, GlaxoSmithKline, Novartis, Pfizer and Takeda. More information
is available at www.thesgc.org
About 1DegreeBio Inc.
1DegreeBio.org is the world’s largest open-access antibody database.
Listing more than 800,000 products from 160 suppliers, 1DegreeBio has
all the information researchers need to find the right products for
their research, including quality validation data, citations, user
reviews and ratings. http://1degreebio.org
The 1DegreeBio Epigenetics Portal is the first in a series of sub-sites
designed to meet the needs of specific research areas. The next portal
will be geared toward stem cell researchers, and will launch in July